Bausch Health's (BHC) Xifaxan Settlement is 'Favorable' - Deutsche Bank
Tweet Send to a Friend
Deutsche Bank analyst Gregg Gilbert reiterated a Buy rating and $30 price target on Bausch Health Companies (NYSE: BHC) on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
